Cytrellis Biosystems
CompanyUnited States
Cytrellis Biosystems develops one asset, in human trials (ellacor in gene expression). Mostly device; based in the United States.
- 1
- Asset
- Furthest stage
- Human trials
- 0
- Trials
- 0
- Signals
Pipeline
1Micro-coring technology that removes micro-columns of skin to reduce skin laxity and wrinkles
Human trials, Device, gene expression, glp1 agonist
Full company profiles: pipeline, trials, funding and people.